Hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been described more
than 50 years ago. Similarly, to other clinical conditions, in which impairment of host immune …

Background As nucleos/tide analogue (NA) therapy (eg entecavir and tenofovir) for chronic
Hepatitis B virus (HBV) infection becomes more widely indicated and available …

Objectives. There are no detailed reports on the long‐term outcome of patients treated with
tenofovir disoproxil fumarate (TDF) compared with entecavir (ENT) following liver …

There are several treatment protocols for acute viral hepatitis, and it is critical to recognize
acute hepatitis in its earliest stages. Public health measures to control these infections also …

Hepatitis B virus (HBV) is a hepatotropic, partially double-stranded DNA virus that replicates
by reverse transcription and is a major cause of chronic liver disease and hepatocellular …

Tenofovir is wildly used to treat chronic hepatitis B (CHB) infection due to good potency and
high genetic barrier to drug resistance. To date, it remains controversial whether hepatitis B …

Nucleot (s) ide analogues, the current antiviral treatments against chronic hepatitis B (CHB)
infection, are non-curative due to their inability to eliminate covalently closed circular DNA …

We investigated Nucleos (t) ide-analogue (NA)-resistance mutations (mt) in 142 treatment-
naive children with Chronic Hepatitis B (CHB), using a sensitive co-amplification at lower …

Nucleos (t) ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects
with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists …

Simple Summary It is still controversial whether tenofovir disoproxil fumarate (TDF) has a
lower risk of hepatocellular carcinoma (HCC) development than entecavir (ETV) in patients …